Literature DB >> 22236853

Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.

H J Kim1, H K Kwak, J Lee, Y J Yun, J S Lee, M S Lee, S Y Min, S K Park, H S Kang, Y H Maeng, S Y Kim, S Y Kim, Y H Kook, Y R Kim, K H Lee.   

Abstract

BACKGROUND: Pyrazinamide (PZA), one of the most effective anti-tuberculosis drugs, becomes toxic to Mycobacterium tuberculosis when converted to pyrazinoic acid by pyrazinamidase (PZase). PZA resistance is caused mainly by the loss of enzyme activity by mutation.
OBJECTIVE: To investigate the patterns of pncA mutations in PZA-resistant mycobacteria isolated from South Korean patients.
METHODS: Mycobacterial isolates with clinically proven drug resistance were cultured to determine susceptibility to anti-tuberculosis agents. pncA mutations were recognised by sequencing and compared with the relevant wild-type DNA sequence.
RESULTS: Among 108 isolates, 102 were successfully cultured and underwent drug susceptibility testing; all were multidrug-resistant (MDR). pncA mutations were found in 86 cultured isolates (85.1%): 55 (84.6%) in MDR and 31 (86.1%) in extensively drug-resistant isolates. Substitution of a single nucleotide was most common. The most frequent mutations were a deletion that caused a frameshift at nucleotide (nt) 71, a substitution at nt 403 and a substitution at nt 11. Combined, these accounted for ≈ 40% of all mutations. However, 15 samples (14.9%) with defective PZase activity showed no mutation.
CONCLUSION: pncA mutation in M. tuberculosis is a major mechanism of PZA resistance in MDR isolates from patients in South Korea. The patterns of mutation might be more scattered and diverse. DNA-based diagnosis of PZA resistance has potential for the rapid detection of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236853     DOI: 10.5588/ijtld.10.0739

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  16 in total

1.  Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Authors:  Kathy Williams; Austin Minkowski; Opokua Amoabeng; Charles A Peloquin; Dinesh Taylor; Koen Andries; Robert S Wallis; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

2.  Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China.

Authors:  Qiang Xia; Li-Li Zhao; Feng Li; Yu-Mei Fan; Yuan-Yuan Chen; Bei-Bei Wu; Zheng-Wei Liu; Ai-Zhen Pan; Min Zhu
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

3.  Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium tuberculosis in New York City.

Authors:  Dawn Verdugo; Dorothy Fallows; Shama Ahuja; Neil Schluger; Barry Kreiswirth; Barun Mathema
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

4.  Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009.

Authors:  Ekaterina V Kurbatova; Joseph S Cavanaugh; Tracy Dalton; Eleanor S Click; J Peter Cegielski
Journal:  Clin Infect Dis       Date:  2013-07-09       Impact factor: 9.079

Review 5.  'Z(S)-MDR-TB' versus 'Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility.

Authors:  Ying Zhang; Kwok Chiu Chang; Chi-Chiu Leung; Wing Wai Yew; Brigitte Gicquel; Dorothy Fallows; Gilla Kaplan; Richard E Chaisson; Wenhong Zhang
Journal:  Emerg Microbes Infect       Date:  2012-07-25       Impact factor: 7.163

6.  Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries.

Authors:  Ekaterina V Kurbatova; Tracy Dalton; Julia Ershova; Thelma Tupasi; Janice Campos Caoili; Martie Van Der Walt; Charlotte Kvasnovsky; Martin Yagui; Jaime Bayona; Carmen Contreras; Vaira Leimane; Laura E Via; HeeJin Kim; Somsak Akksilp; Boris Y Kazennyy; Grigory V Volchenkov; Ruwen Jou; Kai Kliiman; Olga V Demikhova; J Peter Cegielski
Journal:  Emerg Infect Dis       Date:  2015-06       Impact factor: 6.883

7.  Isolation of Vibrio vulnificus from Seawater and Emerging Vibrio vulnificus Septicemia on Jeju Island.

Authors:  Keun Hwa Lee; Sang Taek Heo; Young Ree Kim; Ig-Chan Pang
Journal:  Infect Chemother       Date:  2014-06-20

8.  pncA Mutations in the Specimens from Extrapulmonary Tuberculosis.

Authors:  Jaechun Lee; Yeo-Jun Yun; Cheah Yoke Kqueen; Jong Hoo Lee; Hee-Youn Kim; Young Ree Kim; Yoon-Hoh Kook; Keun Hwa Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-06-29

Review 9.  A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis.

Authors:  Michael G Whitfield; Heidi M Soeters; Robin M Warren; Talita York; Samantha L Sampson; Elizabeth M Streicher; Paul D van Helden; Annelies van Rie
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

10.  Design, Synthesis and Antitubercular Evaluation of Novel Series of Pyrazinecarboxamide Metal Complexes.

Authors:  Mohsin Ali; Mansoor Ahmed; Saleem Hafiz; Mustafa Kamal; Majid Mumtaz; Seyed Abdulmajid Ayatollahi
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.